News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Array BioPharma, Inc. (ARRY) to Present at the Bank of America (BAC) Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference



5/8/2013 7:17:36 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOULDER, Colo., May 8, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare conference in New York City. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Event:

Bank of America Merrill Lynch Healthcare Conference

Date:

Thursday, May 16, 2013

Time:

11:20 a.m. PDT

Location:

Encore at the Wynn, Las Vegas, NV



Event:

UBS Global Healthcare Conference

Date:

Tuesday, May 21, 2013

Time:

8:30 a.m. EDT

Location:

Sheraton New York Hotel, NYC, NY

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013. In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013. AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib (an Array-invented drug) in non-small cell lung cancer and thyroid cancer during the second half of 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche). For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto


Array BioPharma Inc.


303-386-1193


thaugeto@arraybiopharma.com

SOURCE Array BioPharma Inc.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES